XML 47 R36.htm IDEA: XBRL DOCUMENT v3.6.0.2
Segment Information (Tables)
 6 Months Ended
Dec. 31, 2016
Segment Reporting [Abstract]  
Net Revenue and Segment EBITDA
The following tables include net revenue and Segment EBITDA during the three and six months ended December 31, 2016 and December 31, 2015:
 
Three Months Ended  
 December 31,
 
Six Months Ended  
 December 31,
(Dollars in millions)
2016
 
2015
 
2016
 
2015
Softgel Technologies
 
 
 
 
 
 
 
Net revenue
$
201.9

 
$
181.1

 
$
388.3

 
$
365.1

Segment EBITDA
43.4

 
34.8

 
73.9

 
69.4

Drug Delivery Solutions
 
 
 
 
 
 
 
Net revenue
214.0

 
204.1

 
405.3

 
377.7

Segment EBITDA
50.0

 
62.1

 
92.0

 
99.6

Clinical Supply Services
 
 
 
 
 
 
 
Net revenue
77.0

 
76.9

 
152.0

 
154.5

Segment EBITDA
11.6

 
13.4

 
22.1

 
27.4

Inter-segment revenue elimination
(9.2
)
 
(7.2
)
 
(19.7
)
 
(19.4
)
Unallocated Costs (1)
(19.8
)
 
(12.9
)
 
(40.1
)
 
(26.8
)
Combined Totals:
 
 
 
 
 
 
 
Net revenue
$
483.7

 
$
454.9

 
$
925.9

 
$
877.9

 
 
 
 
 
 
 
 
EBITDA from continuing operations
$
85.2

 
$
97.4

 
$
147.9

 
$
169.6


(1)
Unallocated costs includes equity-based compensation, certain acquisition-related costs, impairment charges, certain other corporate directed costs, certain customer claim expenses related to the Beinheim facility suspension and other costs that are not allocated to the segments as follows:
 
Three Months Ended  
 December 31,
 
Six Months Ended  
 December 31,
(Dollars in millions)
2016
 
2015
 
2016
 
2015
Impairment charges and gain/(loss) on sale of assets
$
(0.5
)
 
$
0.1

 
$
(0.5
)
 
$
(1.1
)
Equity compensation
(4.9
)
 
(2.6
)
 
(11.8
)
 
(5.1
)
Restructuring and other special items (2)
(7.2
)
 
(4.2
)
 
(13.1
)
 
(6.2
)
Noncontrolling interest
—

 
0.1

 
—

 
0.3

Other income/(expense), net (3)
1.8

 
3.5

 
3.9

 
2.9

Non-allocated corporate costs, net
(9.0
)
 
(9.8
)
 
(18.6
)
 
(17.6
)
Total unallocated costs
$
(19.8
)
 
$
(12.9
)
 
$
(40.1
)
 
$
(26.8
)


(2)
Segment results do not include restructuring and other costs associated with certain customer claim expenses related to the Beinheim facility suspension and certain acquisition-related costs.
(3)
Amounts primarily relate to foreign currency translation gains and losses during all periods presented.
Reconciliation of Earnings/(Loss) from Continuing Operations to EBITDA
Provided below is a reconciliation of EBITDA from continuing operations to earnings/(loss) from continuing operations, the closest related measure prepared in accordance with GAAP:
 
Three Months Ended  
 December 31,
 
Six Months Ended  
 December 31,
(Dollars in millions)
2016
 
2015
 
2016
 
2015
Earnings from continuing operations
$
17.4

 
$
30.6

 
$
22.0

 
$
42.4

Depreciation and amortization
35.5

 
35.2

 
71.3

 
70.7

Interest expense, net
22.8

 
22.3

 
44.9

 
45.0

Income tax (benefit)/expense
9.5

 
9.2

 
9.7

 
11.2

Noncontrolling interest
—

 
0.1

 
—

 
0.3

EBITDA from continuing operations
$
85.2

 
$
97.4

 
$
147.9

 
$
169.6
Total Assets for Each Segment and Reconciling in Consolidated Financial Statements
The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements: 
(Dollars in millions)
December 31, 
 2016
 
June 30, 
 2016
Assets
 
 
 
Softgel Technologies
$
1,292.9

 
$
1,446.4

Drug Delivery Solutions
1,574.9

 
1,475.7

Clinical Supply Services
538.3

 
578.9

Corporate and eliminations
(251.8
)
 
(409.9
)
Total assets
$
3,154.3

 
$
3,091.1